| Thomas Morrison, | |
|
124 S Madison Ave, Aurora, MO 65605-1427 | |
| (417) 678-4136 | |
| (417) 678-2014 |
| Full Name | Thomas Morrison |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 124 S Madison Ave, Aurora, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699111963 | NPI | - | NPPES |
| 600282800 | Medicaid | MO | |
| 1609865047 | Other | MO | AURORA PROFESSIONAL PHARMACY NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 040857 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Morrison, 124 S Madison Ave, Aurora, MO 65605-1427 Ph: () - | Thomas Morrison, 124 S Madison Ave, Aurora, MO 65605-1427 Ph: (417) 678-4136 |
News Archive
Bovine respiratory disease complex has multiple causes. It's sometimes hard to classify and predict. It also costs the beef industry more than any other disease - an estimated $690 million in 2006, according to one report.
L-3 Communications announced today that it has entered into an agreement to acquire Insight Technology Incorporated. Insight develops and manufactures mission critical night vision and electro-optical equipment including laser aiming and illumination devices, laser rangefinders, laser markers and designators, night vision goggles and monoculars, and thermal imaging systems.
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
› Verified 3 days ago
Allison Patton, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 124 S Madison Ave, Aurora, MO 65605 Phone: 417-678-4136 | |
John Tucker Dunham, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3020 S Elliott Ave, Aurora, MO 65605 Phone: 417-678-6006 | |
Bryan Porter, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3020 S Elliott Ave, Aurora, MO 65605 Phone: 417-678-6006 |